Dr Louise Fleming completed her undergraduate degree in medicine at the University of Manchester before moving to London for postgraduate training in Paediatrics. This included an 18 month VSO/RCPCH Fellowship in The Gambia.
Dr Fleming undertook postgraduate research at NHLI and the Royal Brompton Hospital, funded by the British Lung Foundation, under the supervision of Professor Andrew Bush and Dr Nicola Wilson. She carried out a randomised controlled trial investigating the use of inflammatory markers to guide management in children with severe asthma leading to the award of an MD degree.
Dr Fleming’s research interests include characterizing problematic severe asthma; monitoring asthma including use of biomarkers; determinants of adherence; identification of novel therapeutic targets and non-pharmacological management of asthma including behavior change. She is the clinical lead for asthma at the Royal Brompton where she has developed the difficult asthma protocol and the National Registry for children with difficult asthma. She is a member of the BTS Specialist Advisory Group for Severe Asthma, a member of the BTS/SIGN clinical guidelines group and Chair of the Asthma UK Health Professionals Council.
et al., 2019, Pulmonary type2 innate lymphoid cells in paediatric severe asthma: phenotype and response to steroids, European Respiratory Journal, ISSN:0903-1936
et al., 2019, GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents., Eur Respir J, Vol:53
et al., 2019, Advances in the aetiology, management, and prevention of acute asthma attacks in children, Lancet Child & Adolescent Health, Vol:3, ISSN:2352-4642, Pages:354-364
et al., 2019, IL-17-high asthma with features of a psoriasis immunophenotype, Journal of Allergy and Clinical Immunology, ISSN:0091-6749
et al., 2019, Biologics for paediatric severe asthma: Trick or TREAT?, The Lancet Respiratory Medicine, ISSN:2213-2600